Wednesday, 8 October 2014

Top 50 Big Biotech Partnering and M&A Deal Trends, New Report Launched

Top 50 Big Biotech Partnering and M&A Deal Trends

The Top 50 Big Biotech Partnering and M&A Deal Trends report provides comprehensive and in-depth insight into the dealmaking interests and activity of the worlds leading fifty big biotech companies.

Description
The Top 50 Big Biotech Partnering and M&A Deal Trends report provides the most comprehensive and in-depth insight into the dealmaking interests and activity of the worlds leading fifty big biotech companies.

Top 50 Big Biotech Partnering and M&A Deal Trends provides the user with the following key benefits:
  • Detailed partnering activity profiles for each of the top 50 big biotech companies
  • Over 300 charts showing a company’s dealmaking activity since 2009, allowing quick identification potential partners
  • Partnering therapy focus revealed
  • Partnering activity since 2009 – number of deals per year
  • Full listing of partnering deals
  • Activity by deal type
  • Activity by industry sector
  • Activity by phase of development
  • Activity by technology type
  • Activity by therapeutic area
  • Comprehensive access to over 1,500 partnering deals as recorded at Current Agreement, together with contract documents if available
  • Insight into the terms included in a partnering agreement, together with real world clause examples, via contract documents
  • Understand the key deal terms the company has agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies


The Partnering Deals and Alliances with Big Biotech report provides the most comprehensive and in-depth insight into the dealmaking interests and activity of the worlds leading fifty big biotech companies.

This premier report provides all the information you require to better understand big biotech partnering.

One of the key aspects of partnering is finding those companies that are potential candidates for the development and commercialization of the next generation of therapies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.

Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the company’s business development objectives. Over 300 charts allow quick understanding of each big biotech companies dealmaking trends over the last four years.

This report contains over 1,500 links to online copies of actual partnering deals as recorded at Current Agreement, together with contract documents if submitted to the Securities Exchange Commission by big biotech and their partners.

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of big biotech’s dealmaking and business activities.

Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading big biotech companies based on 2013 pharmaceutical revenues and dealmaking activity since 2009.

Chapter 3 reviews the top partnering and M&A deals of 2009-2014 according to reported deal size.

Chapter 4 provides a summary on best practice on how to submit an opportunity to big biotech, to ensure building of relationships and to obtain a prompt assessment and response from the business development function of the prospective partner.

Chapter 5 lists forthcoming partnering events where valuable face to face meetings with big biotech provide a highly effective means of obtaining interest in novel opportunities. These events are where dealmaking gets initiated through numerous back to back meetings.

The main body of the report is provided in chapter 6. In-depth profiles of every big biotech company provide everything required to assess the suitability of a company as a prospective partner. Each profile includes a company overview, partnering activity according to deal type, phase of development, therapy area and technology type.

Each company profile provides a comprehensive listing of deal records available at Current Agreements, each of which links direct to an online copy of the actual deal record plus contract document if filed with the SEC.

One of the key aspects of partnering is conducting due diligence on a partner to determine under what terms a prospective partner agrees to a partnering relationship.

Understanding the flexibility of a prospective partner’s negiotated deals terms provides critical insight into the negotiation process in termsof what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

This data driven report contains over 2,000 links to online copies of actual deal records at Current Agreements and contract documents, where submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

In addition, contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
In summary, the report provides the reader with the tools necessary to make successful contact with the right big biotech partners effectively and efficiently.

Spanning over 529 pages, “Top 50 Big Biotech Partnering and M&A Deal Trends” report covering the Introduction, Big biotech top 50 dealmaking activity, Top big biotech deals by value, Submitting Opportunities to Big biotech, Forthcoming big biotech partnering events, Big Biotech Company Profiles, Resources, Appendices.

Know more about this report at – http://mrr.cm/ZDx

Find all Biotechnology Reports at: http://www.marketresearchreports.com/biotechnology

Salix Pharmaceuticals Partnering 2009-2014, New Report Launched

Salix Pharmaceuticals Partnering 2009-2014

This report provides all the information you require to better understand Salix Pharmaceuticals and its partnering interests and activities over the past five years.

Description
The Partnering Agreements with Salix Pharmaceuticals 2009-2014 report provides an in-depth insight into the partnering interests and activities of one of the worlds leading biopharma companies.

This report provides all the information you require to better understand Salix Pharmaceuticals and its partnering interests and activities over the past five years.

On demand company reports are prepared upon purchase to ensure inclusion of the most up to date deal and company data.

One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.

Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the company’s business development objectives.

The initial chapters of this report provide an orientation of big biotech's dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading big biotech companies based on 2013 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the leading partnering and M&A 2009 to present date based on headline value.

Chapter 4 provides details on how to approach big biotech companies with partnering opportunities whilst chapter 5 lists forthcoming partnering events and conferences where big biotech companies will be present to discuss opportunities face to face.

The main body of the report is provided in chapter 6. A profile of the company provides everything required to assess the suitability of a company as a prospective partner. This includes a company overview, partnering interests, partnering activity according to deal type, industry sector, phase of development, and therapy area. The profile also includes in-depth contact information for individuals within the business development function.

The deals are listed by deal type, stage of development and therapy focus, allowing easy access to deals and alliances of interest. Every deal record links to an online, live version of the deal record at the Current Agreements deals and alliances database. Where available, deal records also include the contract document as disclosed at the SEC.

One of the key aspects of partnering is conducting due diligence on a partner to determine under what terms a prospective partner agrees to a partnering relationship.

Understanding the flexibility of prospective partners’ negotiated deals terms provides critical insight into the negotiation process in termsof what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

In addition, contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each parties ability to derive value from the deal.

In summary, the report provides the user with the tools to make successful contact with the right partners effectively and efficiently.

Benefits
This report provides all the information you require to better understand Pharmacyclics and its partnering interests and activities over the past five years.

Spanning over 100 pages, “Salix Pharmaceuticals Partnering 2009-2014” report covering the Introduction, Big biotech top 50 and dealmaking activity, Top Salix Pharmaceuticals deals by value, Submitting Opportunities to Prospective Partners, Forthcoming partnering events, Company Profile. The report covered 1 company - Salix Pharmaceuticals

Know more about this report at – http://mrr.cm/ZDg

Find all Diagnostics Reports at: http://www.marketresearchreports.com/diagnostics

Pharmacyclics Partnering 2009-2014, New Report Launched

Pharmacyclics Partnering 2009-2014

This report provides all the information you require to better understand Pharmacyclics and its partnering interests and activities over the past five years.

Description
The Partnering Agreements with Pharmacyclics 2009-2014 report provides an in-depth insight into the partnering interests and activities of one of the worlds leading biopharma companies.

This report provides all the information you require to better understand Pharmacyclics and its partnering interests and activities over the past five years.

On demand company reports are prepared upon purchase to ensure inclusion of the most up to date deal and company data.

One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.

Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the company’s business development objectives.

The initial chapters of this report provide an orientation of big biotech's dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading big biotech companies based on 2013 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the leading partnering and M&A 2009 to present date based on headline value.

Chapter 4 provides details on how to approach big biotech companies with partnering opportunities whilst chapter 5 lists forthcoming partnering events and conferences where big biotech companies will be present to discuss opportunities face to face.

The main body of the report is provided in chapter 6. A profile of the company provides everything required to assess the suitability of a company as a prospective partner. This includes a company overview, partnering interests, partnering activity according to deal type, industry sector, phase of development, and therapy area. The profile also includes in-depth contact information for individuals within the business development function.

The deals are listed by deal type, stage of development and therapy focus, allowing easy access to deals and alliances of interest. Every deal record links to an online, live version of the deal record at the Current Agreements deals and alliances database. Where available, deal records also include the contract document as disclosed at the SEC.

One of the key aspects of partnering is conducting due diligence on a partner to determine under what terms a prospective partner agrees to a partnering relationship.

Understanding the flexibility of prospective partners’ negotiated deals terms provides critical insight into the negotiation process in termsof what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

In addition, contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each parties ability to derive value from the deal.

In summary, the report provides the user with the tools to make successful contact with the right partners effectively and efficiently.

Benefits
Partnering Agreements with Pharmacyclics report provides the user with the following key benefits:

  • Detailed company profile of the company
  • Partnering interests and therapy focus revealed
  • Partnering activity since 2009 – number of deals per year
  • Partnering activity for 2009-present
  • Activity by deal type
  • Activity by phase of development
  • Activity by therapeutic area
  • List of recent partner companies
  • Detailed listing of all partnering deals since 2009
  • Comprehensive access to actual contracts entered into by the company and its partners*
  • Insight into the terms included in a partnering agreement
  • Understand the key deal terms the company has agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies


Spanning over 100 pages, “Pharmacyclics Partnering 2009-2014” report covering the Introduction, Big biotech top 50 and dealmaking activity, Top Pharmacyclics deals by value, Submitting Opportunities to Prospective Partners, Forthcoming partnering events, Company Profile. The report covered 1 company – Pharmacyclics

Know more about this report at – http://mrr.cm/ZDM

Find all Healthcare Reports at: http://www.marketresearchreports.com/healthcare

Molecular Diagnostics Partnering Terms and Agreements, New Report Launched

Molecular Diagnostics Partnering Terms and Agreements

The Molecular Diagnostics Partnering Terms & Agreements provides comprehensive understanding and unprecedented access to the molecular diagnostics partnering deals and agreements entered into by the worlds leading healthcare companies.

Description
The Molecular Diagnostics Partnering Terms and Agreements report provides a detailed understanding and analysis of how and why companies enter molecular diagnostics partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest molecular diagnostics agreements announced in the healthcare sectors.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all molecular diagnostics partnering deals announced since 2009 including financial terms where available including over 300 links to online deal records of actual molecular diagnostics partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

For example, analyzing actual company deals and agreements allows assessment of the following:
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What are the precise rights granted or optioned?
  • What is the payment structure for the deal?
  • How aresalesand payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?


The initial chapters of this report provide an orientation of drug dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in molecular diagnostics dealmaking since 2009, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading molecular diagnostics deals since 2009. Deals are listed by headline value, signed by big pharma, big biotech, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 50 big pharma companies with a brief summary followed by a comprehensive listing of molecular diagnostics deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive listing of the top 50 big biotech companies with a brief summary followed by a comprehensive listing of molecular diagnostics deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of molecular diagnostics partnering deals signed and announced since 2009, where a contract document is available in the public domain. The chapter is organized by stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), specific therapy focus and specific technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in molecular diagnostics partnering and dealmaking since 2009.

In addition, a comprehensive appendix is provided organized by molecular diagnostics partnering company A-Z , deal type definitions and molecular diagnostics partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about molecular diagnostics partnering in the research, development and commercialization of molecular diagnostics technologies and products.

Report scope
Molecular Diagnostics Partnering Agreements is intended to provide the reader with an in-depth understanding and access to molecular diagnostics trends and structure of deals entered into by leading companies worldwide.

Molecular Diagnostics Partnering Agreements includes:

Trends in molecular diagnostics dealmaking in the biopharma industry since 2009
  • Analysis of molecular diagnostics deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to over 300 molecular diagnostics deal records
  • The leading molecular diagnostics deals by value since 2009


In Molecular Diagnostics Partnering Agreements, the available deals are listed by:
  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific diagnostics technology type


Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Molecular Diagnostics Partnering Agreements report provides comprehensive access to available deals and contract documents for over 300 molecular diagnostics deals. Analyzing actual contract agreements allows assessment of the following:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How aresalesand payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?


Benefits
Molecular Diagnostics Partnering Terms and Agreements provides the reader with the following key benefits:

  • In-depth understanding of molecular diagnostics deal trends since 2009
  • Access molecular diagnostics deal headline, upfront, milestone and royalty data
  • Analysis of the structure of molecular diagnostics agreements with numerous real life case studies
  • Comprehensive access to over 300 links to actual infectious vaccines deals entered into by the world’s biopharma companies, together with real world clause examples
  • Identify leading molecular diagnostics deals by value since 2009
  • Identify the most active molecular diagnostics dealmakers since 2009
  • Insight into the terms included in molecular diagnostics agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies


Spanning over 432 pages, “Molecular Diagnostics Partnering Terms and Agreements” report covering the Introduction, Trends in molecular diagnostics dealmaking, Leading molecular diagnostics deals, Big pharma molecular diagnostics deals, Big biotech molecular diagnostics deals, Molecular diagnostics partnering contracts directory, Molecular diagnostics dealmaking directory, Appendices. The report covered companies are - Abbott, Actavis, Watson Pharmaceuticals, Actelion, Allergan, Amgen, Aspen Pharmacare, Astellas, AstraZeneca, Pfizer, Novartis, GSK, Takeda, Bayer, Boehringer Ingelheim

Know more about this report at – http://mrr.cm/ZDf

Find all Pharma and Healthcare Technology Reports at: 

Jazz Pharmaceuticals Partnering 2009-2014, New Report Launched

Jazz Pharmaceuticals Partnering 2009-2014

This report provides all the information you require to better understand Jazz Pharmaceuticals and its partnering interests and activities over the past five years.

Description
The Partnering Agreements with Jazz Pharmaceuticals 2009-2014 report provides an in-depth insight into the partnering interests and activities of one of the worlds leading biopharma companies.

This report provides all the information you require to better understand Jazz Pharmaceuticals and its partnering interests and activities over the past seven years.

On demand company reports are prepared upon purchase to ensure inclusion of the most up to date deal and company data.

One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.

Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the company’s business development objectives.

The initial chapters of this report provide an orientation of big biotech's dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading big biotech companies based on 2013 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the leading partnering and M&A 2009 to present date based on headline value.

Chapter 4 provides details on how to approach big biotech companies with partnering opportunities whilst chapter 5 lists forthcoming partnering events and conferences where big biotech companies will be present to discuss opportunities face to face.

The main body of the report is provided in chapter 6. A profile of the company provides everything required to assess the suitability of a company as a prospective partner. This includes a company overview, partnering interests, partnering activity according to deal type, industry sector, phase of development, and therapy area. The profile also includes in-depth contact information for individuals within the business development function.

The deals are listed by deal type, stage of development and therapy focus, allowing easy access to deals and alliances of interest. Every deal record links to an online, live version of the deal record at the Current Agreements deals and alliances database. Where available, deal records also include the contract document as disclosed at the SEC.

One of the key aspects of partnering is conducting due diligence on a partner to determine under what terms a prospective partner agrees to a partnering relationship.

Understanding the flexibility of prospective partners’ negotiated deals terms provides critical insight into the negotiation process in termsof what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

In addition, contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each parties ability to derive value from the deal.

In summary, the report provides the user with the tools to make successful contact with the right partners effectively and efficiently.

Benefits
Partnering Agreements with Jazz Pharmaceuticals report provides the user with the following key benefits:

  • Detailed company profile of the company
  • Partnering interests and therapy focus revealed
  • Partnering activity since 2009 – number of deals per year
  • Partnering activity for 2009-present
  • Activity by deal type
  • Activity by phase of development
  • Activity by therapeutic area
  • List of recent partner companies
  • Detailed listing of all partnering deals since 2009
  • Comprehensive access to actual contracts entered into by the company and its partners*
  • Insight into the terms included in a partnering agreement
  • Understand the key deal terms the company has agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies


Spanning over 100 pages, “Jazz Pharmaceuticals Partnering 2009-2014” report covering the Introduction, Big biotech top 50 and dealmaking activity, Top Jazz Pharmaceuticals deals by value, Submitting Opportunities to Prospective Partners, Forthcoming partnering events, Company Profile. The report covered 1 company - Jazz Pharmaceuticals

Know more about this report at – http://mrr.cm/ZDY

Find all Pharma and Healthcare Technology Reports at: 


Tuesday, 7 October 2014

Global Joint Venture Partnerships in Pharma, Biotech and Diagnostics, New Report Launched

Global Joint Venture Partnerships in Pharma, Biotech and Diagnostics

The Global Joint Venture Partnerships in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the joint venture partnering agreements entered into by the worlds leading healthcare companies

Description
The Global Joint Venture Partnerships in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the joint venture partnering agreements entered into by the worlds leading healthcare companies.

This new 1st edition, includes:
  • Trends in joint venture deals
  • Joint venture agreement structure
  • Joint venture contract documents
  • Top joint venture deals by value
  • Most active joint venture dealmakers
  • Comprehensive directory of joint venture deals since 2009


This report provides details of the latest joint venture agreements announced in the pharmaceutical, biotechnology and diagnostic sectors.

The report provides details of joint venture agreements from 2009 to end of August 2014.

The report provides a detailed understanding and analysis of how and why companies enter joint venture deals.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all joint venture deals announced since 2009 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual co-promotion and co-marketing contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

Report scope
Global Joint Venture Partnerships in Pharma, Biotech and Diagnostics report is intended to provide the reader with an in-depth understanding of the joint venture trends and structure of deals entered into by leading biopharma companies worldwide.

Global Joint Venture Partnerships in Pharma, Biotech and Diagnostics includes:
  • Trends in joint venture dealmaking in the biopharma industry since 2009
  • Analysis of joint venture deal structure
  • Case studies of real-life joint venture deals
  • Access to over 450 joint venture deal records
  • Detailed access to actual joint venture contract documents
  • The leading joint venture deals by value since 2009
  • Most active joint venture dealmakers since 2009
  • The leading joint venture partnering resources


In Global Joint Venture Partnerships in Pharma, Biotech and Diagnostics, the available contracts are listed by:
  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Therapeutic area
  • Technology area


Each deal title links via Weblink to an online version of deal record as found in the Current Agreements deals and alliances database, providing easy access to each deal record on demand.

The Global Joint Venture Partnerships report provides comprehensive access to records for over 450 joint venture deals. Analyzing actual contract agreements allows assessment of the following:

  • What are the precise joint venture rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How aresalesand payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law


Benefits
Global Joint Venture Partnerships in Pharma, Biotech and Diagnostics provides the reader with the following key benefits:
  • In-depth understanding of joint venture deal trends since 2009
  • Analysis of the structure of joint venture agreements with numerous real life case studies
  • Comprehensive access to over 450 joint venture deals entered into by the world’s biopharma companies, together with contract documents if available
  • Detailed access to actual joint venture contracts entered into by the leading fifty big pharma and big biotech companies
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies
  • Identify leading joint venture deals by value since 2009
  • Identify the most active joint venture dealmakers since 2009
  • Full listing of joint venture deals by company A-Z, headline value, phase of development, deal type, therapy and technology focus


Spanning over 652 pages, 14 Figures “Global Joint Venture Partnerships in Pharma, Biotech and Diagnostics” report covering Executive Summary, Introduction, Trends in joint venture partnerships, Overview of joint venture deal structure, Leading joint venture deals, Bigpharma joint venture deals, Bigbiotech joint venture deals, Joint venture contract directory 2009-2014, Appendix. This report Covered These Companies - Abbott, Actavis, Watson Pharmaceuticals, Actelion, Allergan, Amgen, Aspen Pharmacare, Astellas, AstraZeneca, Pfizer, Novartis, GSK, Takeda, Bayer, Boehringer Ingelheim.

Know more about this report at – http://mrr.cm/ZDp

Regenerative Medicine Partnering Terms and Agreements, New Report Launched

Regenerative Medicine Partnering Terms and Agreements

The Regenerative Medicine Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the regenerative medicine including cell therapy, organ regeneration, stem cells and tissue regeneration partnering deals and agreements entered into by the worlds leading healthcare companies.

Description
The Regenerative Medicine Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the regenerative medicine including cell therapy, organ regeneration, stem cells and tissue regeneration partnering deals and agreements entered into by the worlds leading healthcare companies.

  • Trends in regenerative medicine
  • Deal terms analysis
  • Partnering agreement structure
  • Partnering contract documents
  • Top deals by value
  • Most active dealmakers
  • Average deal terms for regenerative medicine and stem cells


The report provides a detailed understanding and analysis of how and why companies enter regenerative medicine and stem cells partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors regenerative medicine and stem cells technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest regenerative medicine and stem cells agreements including cell therapy agreements announced in the healthcare sector.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all regenerative medicine and stem cells partnering deals announced since 2009 including financial terms where available including over 650 links to online deal records as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

For example, analyzing actual company deals and agreements allows assessment of the following:
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What are the precise rights granted or optioned?
  • What is the payment structure for the deal?
  • How aresalesand payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?


The initial chapters of this report provide an orientation of regenerative medicine dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in regenerative medicine dealmaking since 2009, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading regenerative medicine deals since 2009. Deals are listed by headline value, signed by big pharma and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 50 big pharma companies that are active in rgenerative medicine partnering with a brief summary followed by a comprehensive listing of deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive listing of the top 50 biotech pharma companies that are active in rgenerative medicine partnering with a brief summary followed by a comprehensive listing of deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand

Chapter 6 provides a comprehensive and detailed review of regenerative medicine partnering deals signed and announced since 2009, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc) and specific therapy focus.

Chapter 7 provides a comprehensive and detailed review of all regenerative medicine partnering deals including cell therapy, organ regeneration, stem cells and tissue regeneration signed and announced since 2009. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in regenerative medicine partnering and dealmaking since 2009.

In addition, a comprehensive appendix is provided organized by regenerative medicine partnering company A-Z, deal type and therapy areas. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of regenerative medicine technologies and products.

Benefits
Regenerative Medicine Partnering Terms and Agreements provides the reader with the following key benefits:
  • In-depth understanding of regenerative medicine and stem cells deal trends since 2009
  • Includes cell therapy, organ regeneration, stem cells and tissue regeneration deals
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of regenerative medicine and stem cells agreements with numerous real life case studies
  • Comprehensive access to actual regenerative medicine and stem cells contracts entered into by the world’s biopharma companies, together with real world clause examples
  • Full listing of regenerative medicine and stem cells deals by company A-Z, deal value, deal type, and therapy focus
  • Identify leading regenerative medicine and stem cells deals by value since 2009
  • Identify the most active regenerative medicine and stem cells dealmakers since 2009
  • Detailed access to actual regenerative medicine and stem cells contracts enter into by the leading fifty big pharma companies
  • Insight into the terms included in a regenerative medicine and stem cells agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies


Spanning over 1116 pages, “Regenerative Medicine Partnering Terms and Agreements” report covering the Introduction, Trends in regenerative medicine dealmaking, Leading regenerative medicine deals, Big pharma regenerative medicine deals, Big biotech regenerative medicine deals, Regenerative medicine partnering contracts directory, Regenerative medicine dealmaking by technology type, Appendices.

Know more about this report at – http://mrr.cm/ZDG

To browse more Pharma and Healthcare Reports visit: